Breast CancerFDA Approvals, News & Updates

Trodelvy New Therapy Approved for Triple-Negative Breast Cancer

In April, 2020, the FDA approved Trodelvy for the treatment of adults with metastatic triple-negative breast cancer after 2 or more previous therapies.
June 2020 Vol 6 No 3

On April 22, 2020, the FDA approved Trodelvy (sacituzumab govitecan-hziy; from Immunomedics) for the treatment of adults with metastatic (spreading) triple-negative breast cancer, or TNBC, after at least 2 previous therapies.

“Metastatic triple-negative breast cancer is an aggressive form of breast cancer with limited treatment options. Chemotherapy has been the mainstay of treatment for triple-negative breast cancer. The approval of Trodelvy today represents a new targeted therapy for patients living with this aggressive malignancy,” said Richard Pazdur, M.D., Director of the FDA’s Oncology Center of Excellence.

Trodelvy is a Trop-2–directed antibody and topoi­somerase inhibitor drug conjugate, meaning that the drug targets the Trop-2 receptor that promotes the growth and spread of cancer cells, and it is linked to a topoisomerase inhibitor, which kills cancer cells.

About 20% of patients with breast cancers have triple-negative breast cancer, meaning they don’t have any of the 3 biomarkers often seen in breast cancer, including estrogen receptor (or ER), progesterone receptor (or PR), and HER2. Therefore, triple-­negative breast cancer doesn’t respond to hormone therapies that target ER, PR, or HER2.

Among the 108 patients included in the clinical trial that led to the FDA approval of Trodelvy, the tumor was shrinking in response to therapy with Trodelvy in about one-third (33%) of the patients. The average duration of the response was 7.7 months, ranging from 6 months to more than 12 months.

The most common side effects with Trodelvy were nausea, neutropenia (reduced white blood cells), diarrhea, fatigue, anemia, vomiting, hair loss, constipation, decreased appetite, rash, and abdominal pain.

Recommended For You
Breast Cancer
Tukysa Improves Survival in Patients with HER2-Positive Breast Cancer that Has Spread to the Brain
By Meg Barbor, MPH
The new cancer drug Tukysa (tucatinib), when given in combination with Herceptin (trastuzumab) and capecitabine, dramatically improved outcomes for patients with HER2-positive advanced breast cancer that has spread to the brain, according to data presented by Nancy U. Lin, MD, Associate Chief, Division of Breast Oncology, Dana-Farber Cancer Institute, Boston, MA, at the 2020 ASCO annual meeting.
Breast Cancer
Adding Kisqali to Endocrine Therapy Increases Survival in Patients with Advanced Breast Cancer and Visceral Metastases
By Meg Barbor, MPH
Metastatic breast cancer is cancer that has spread beyond the breast to other parts of the body. Visceral metastases refer to cancer that has spread to the internal organs of the body, specifically those within the chest (such as the heart or lungs) or abdomen (such as the liver, pancreas, or intestines).
Breast Cancer
Piqray plus Faslodex Effective in HR-Positive Advanced Breast Cancer with PIK3CA Mutation After Endocrine and Targeted Therapy
By Chase Doyle
Induction treatment with endocrine and targeted therapies has significantly improved survival for patients with hormone receptor (HR)-positive advanced breast cancer, but over time almost all patients stop responding to therapy.
FDA Approvals, News & Updates
On August 5, 2020, the FDA accelerated the approval of Blenrep (belantamab mafodotin-blmf; from GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Last modified: June 29, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.